{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T00:18:59Z","timestamp":1795220339299,"version":"4.10.3"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jsat.2021.108521","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T23:44:42Z","timestamp":1622677482000},"page":"108521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Precision dosing of methadone during pregnancy: A pharmacokinetics virtual clinical trials study"],"prefix":"10.1016","volume":"130","author":[{"given":"Raj K.S.","family":"Badhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind","family":"Gittins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jsat.2021.108521_bb0005","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/11597440-000000000-00000","article-title":"Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: A database for parameters required in physiologically based pharmacokinetic modelling","volume":"51","author":"Abduljalil","year":"2012","journal-title":"Clinical Pharmacokinetics"},{"issue":"5","key":"10.1016\/j.jsat.2021.108521_bb0010","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s40262-019-00836-3","article-title":"Fetal physiologically based pharmacokinetic models: Systems information on fetal blood components and binding proteins","volume":"59","author":"Abduljalil","year":"2020","journal-title":"Clinical Pharmacokinetics"},{"issue":"4","key":"10.1016\/j.jsat.2021.108521_bb0015","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jat\/bkw135","article-title":"Tell-tale SNPs: The role of CYP2B6 in methadone fatalities","volume":"41","author":"Ahmad","year":"2017","journal-title":"Journal of Analytical Toxicology"},{"key":"10.1016\/j.jsat.2021.108521_bb0020","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.bcp.2018.02.020","article-title":"Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics","volume":"153","author":"Ahmad","year":"2018","journal-title":"Biochemical Pharmacology"},{"issue":"4","key":"10.1016\/j.jsat.2021.108521_bb0025","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jsat.2011.05.002","article-title":"Changes in methadone maintenance therapy during and after pregnancy","volume":"41","author":"Albright","year":"2011","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"8","key":"10.1016\/j.jsat.2021.108521_bb0030","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/jphp.13281","article-title":"Precision dosing-based optimisation of paroxetine during pregnancy for poor and ultrarapid CYP2D6 metabolisers: A virtual clinical trial pharmacokinetics study","volume":"72","author":"Almurjan","year":"2020","journal-title":"The Journal of Pharmacy and Pharmacology"},{"key":"10.1016\/j.jsat.2021.108521_bb0035","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.drugalcdep.2019.03.013","article-title":"The optimization of methadone dosing whilst treating with rifampicin: A pharmacokinetic modeling study","volume":"200","author":"Badhan","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.jsat.2021.108521_bb0040","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1097\/ALN.0000000000000172","article-title":"Patterns of opioid utilization in pregnancy in a large cohort of commercial insurance beneficiaries in the United States","volume":"120","author":"Bateman","year":"2014","journal-title":"Anesthesiology"},{"issue":"8","key":"10.1016\/j.jsat.2021.108521_bb0045","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/jp.2015.22","article-title":"Growth and developmental outcome of infants with in-utero exposure to methadone vs buprenorphine","volume":"35","author":"Bier","year":"2015","journal-title":"Journal of Perinatology"},{"issue":"5","key":"10.1016\/j.jsat.2021.108521_bb0050","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/0002-9378(75)90461-5","article-title":"Methadone assays in pregnant women and progeny","volume":"121","author":"Blinick","year":"1975","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"2","key":"10.1016\/j.jsat.2021.108521_bb0055","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00213-012-2833-7","article-title":"Pharmacologic evidence to support clinical decision making for peripartum methadone treatment","volume":"225","author":"Bogen","year":"2013","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.jsat.2021.108521_bb0060","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mcp.2001.116793","article-title":"Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate","volume":"70","author":"Boulton","year":"2001","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"12","key":"10.1016\/j.jsat.2021.108521_bb0065","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.1128\/AAC.01229-13","article-title":"Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance","volume":"57","author":"Bruce","year":"2013","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"1","key":"10.1016\/j.jsat.2021.108521_bb0070","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1742-7843.2010.00628.x","article-title":"Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: A reconciliation","volume":"108","author":"Chang","year":"2011","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"issue":"12","key":"10.1016\/j.jsat.2021.108521_bb0075","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1111\/j.1360-0443.2010.03120.x","article-title":"Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis","volume":"105","author":"Cleary","year":"2010","journal-title":"Addiction"},{"issue":"8","key":"10.1016\/j.jsat.2021.108521_bb0080","first-page":"985","article-title":"Human cytochrome P4502B6: Interindividual hepatic expression, substrate specificity, and role in procarcinogen activation","volume":"25","author":"Code","year":"1997","journal-title":"Drug Metabolism and Disposition"},{"issue":"2","key":"10.1016\/j.jsat.2021.108521_bb0085","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1365-2125.2004.02116.x","article-title":"Bioavailabilities of rectal and oral methadone in healthy subjects","volume":"58","author":"Dale","year":"2004","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1016\/j.jsat.2021.108521_bb0090","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jsat.2014.06.001","article-title":"Evidence-based treatment for opioid disorders: A 23-year national study of methadone dose levels","volume":"47","author":"D'Aunno","year":"2014","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"5","key":"10.1016\/j.jsat.2021.108521_bb0095","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/bcp.12685","article-title":"Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women","volume":"80","author":"De Sousa Mendes","year":"2015","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"5","key":"10.1016\/j.jsat.2021.108521_bb0100","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/AOG.0000000000000208","article-title":"Increase in prescription opioid use during pregnancy among Medicaid-enrolled women","volume":"123","author":"Desai","year":"2014","journal-title":"Obstetrics and Gynecology"},{"issue":"2","key":"10.1016\/j.jsat.2021.108521_bb0105","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1124\/dmd.112.047118","article-title":"Quantitative prediction of CYP2B6 induction by estradiol during pregnancy: Potential explanation for increased methadone clearance during pregnancy","volume":"41","author":"Dickmann","year":"2013","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.jsat.2021.108521_bb0110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1747-597X-6-9","article-title":"There is no age limit for methadone: A retrospective cohort study","volume":"6","author":"D\u00fcrsteler-MacFarland","year":"2011","journal-title":"Substance Abuse Treatment, Prevention, and Policy"},{"issue":"14","key":"10.1016\/j.jsat.2021.108521_bb0115","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","article-title":"Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence","volume":"41","author":"Eap","year":"2002","journal-title":"Clinical Pharmacokinetics"},{"issue":"5","key":"10.1016\/j.jsat.2021.108521_bb0120","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/sj.clpt.6100120","article-title":"Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers","volume":"81","author":"Eap","year":"2007","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"10","key":"10.1016\/j.jsat.2021.108521_bb0125","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2165\/00003088-200645100-00005","article-title":"Development and evaluation of a generic physiologically based pharmacokinetic model for children","volume":"45","author":"Edginton","year":"2006","journal-title":"Clinical Pharmacokinetics"},{"issue":"4","key":"10.1016\/j.jsat.2021.108521_bb0130","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2125.1999.00921.x","article-title":"Methadone N-demethylation in human liver microsomes: Lack of stereoselectivity and involvement of CYP3A4","volume":"47","author":"Foster","year":"1999","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"7","key":"10.1016\/j.jsat.2021.108521_bb0135","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1124\/dmd.115.064352","article-title":"Differences in methadone metabolism by CYP2B6 variants","volume":"43","author":"Gadel","year":"2015","journal-title":"Drug Metabolism and Disposition"},{"issue":"9","key":"10.1016\/j.jsat.2021.108521_bb0140","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1128\/AAC.00478-15","article-title":"Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone","volume":"59","author":"Garimella","year":"2015","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"3","key":"10.1016\/j.jsat.2021.108521_bb0145","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/089033449701300312","article-title":"Methadone levels in breast milk","volume":"13","author":"Geraghty","year":"1997","journal-title":"Journal of Human Lactation"},{"issue":"4","key":"10.1016\/j.jsat.2021.108521_bb0150","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/15287390490273550","article-title":"Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: Implications for assessing children's risks from environmental agents","volume":"67","author":"Ginsberg","year":"2004","journal-title":"Journal of Toxicology and Environmental Health. Part A"},{"key":"10.1016\/j.jsat.2021.108521_bb0155","author":"Global Drug Survey"},{"issue":"6","key":"10.1016\/j.jsat.2021.108521_bb0160","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2125.2010.03759.x","article-title":"(R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy","volume":"70","author":"Gordon","year":"2010","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1016\/j.jsat.2021.108521_bb0165","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.clp.2013.05.004","article-title":"Management of neonatal abstinence syndrome from opioids","volume":"40","author":"Grim","year":"2013","journal-title":"Clinics in Perinatology"},{"issue":"1","key":"10.1016\/j.jsat.2021.108521_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/ADM.0b013e318159d81a","article-title":"Management of addiction disorders in pregnancy","volume":"2","author":"Helmbrecht","year":"2008","journal-title":"Journal of Addiction Medicine"},{"issue":"4","key":"10.1016\/j.jsat.2021.108521_bb0175","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/clpt.1987.47","article-title":"Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain","volume":"41","author":"Inturrisi","year":"1987","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"3","key":"10.1016\/j.jsat.2021.108521_bb0180","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1369-1600.2009.00158.x","article-title":"Effect of saquinavir\/ritonavir (1000\/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy","volume":"14","author":"Jamois","year":"2009","journal-title":"Addiction Biology"},{"issue":"1","key":"10.1016\/j.jsat.2021.108521_bb0185","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5055\/jom.2009.0006","article-title":"The opioid exposed newborn: Assessment and pharmacologic management","volume":"5","author":"Jansson","year":"2009","journal-title":"Journal of Opioid Management"},{"issue":"4","key":"10.1016\/j.jsat.2021.108521_bb0190","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1300\/J069v18n04_05","article-title":"Alterations in methadone metabolism during late pregnancy","volume":"18","author":"Jarvis","year":"1999","journal-title":"Journal of Addictive Diseases"},{"issue":"7","key":"10.1016\/j.jsat.2021.108521_bb0195","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/bdd.2081","article-title":"Application of physiologically based pharmacokinetic modeling to predict drug disposition in pregnant populations","volume":"38","author":"Jogiraju","year":"2017","journal-title":"Biopharmaceutics & Drug Disposition"},{"issue":"6","key":"10.1016\/j.jsat.2021.108521_bb0200","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2165\/11632820-000000000-00000","article-title":"Methadone and buprenorphine for the management of opioid dependence in pregnancy","volume":"72","author":"Jones","year":"2012","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.jsat.2021.108521_bb0205","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.drugalcdep.2004.08.027","article-title":"Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone","volume":"78","author":"Jones","year":"2005","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1016\/j.jsat.2021.108521_bb0210","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/ADM.0b013e31815ca2c6","article-title":"Dosing adjustments in postpartum patients maintained on buprenorphine or methadone","volume":"2","author":"Jones","year":"2008","journal-title":"Journal of Addiction Medicine"},{"issue":"3","key":"10.1016\/j.jsat.2021.108521_bb0215","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jsat.2007.10.007","article-title":"Treatment of opioid-dependent pregnant women: Clinical and research issues","volume":"35","author":"Jones","year":"2008","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"5","key":"10.1016\/j.jsat.2021.108521_bb0220","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1080\/10550490802266276","article-title":"Methadone maintenance vs. methadone taper during pregnancy: Maternal and neonatal outcomes","volume":"17","author":"Jones","year":"2008","journal-title":"The American Journal on Addictions"},{"issue":"1","key":"10.1016\/j.jsat.2021.108521_bb0225","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0889-8545(05)70362-4","article-title":"Opioid dependence during pregnancy: Effects and management","volume":"25","author":"Kaltenbach","year":"1998","journal-title":"Obstetrics and Gynecology Clinics of North America"},{"issue":"4","key":"10.1016\/j.jsat.2021.108521_bb0230","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/dmd.112.050161","article-title":"A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women","volume":"41","author":"Ke","year":"2013","journal-title":"Drug Metabolism and Disposition"},{"issue":"3","key":"10.1016\/j.jsat.2021.108521_bb0235","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/bcp.12207","article-title":"Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19","volume":"77","author":"Ke","year":"2014","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"11","key":"10.1016\/j.jsat.2021.108521_bb0240","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s40263-019-00681-9","article-title":"Risk factors associated with the occurrence of neonatal opioid withdrawal syndrome: A review","volume":"33","author":"Kelty","year":"2019","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.jsat.2021.108521_bb0245","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cpdd.326","article-title":"Current concepts in methadone metabolism and transport","volume":"6","author":"Kharasch","year":"2017","journal-title":"Clinical Pharmacology in Drug Development"},{"issue":"2","key":"10.1016\/j.jsat.2021.108521_bb0250","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/ALN.0b013e3182423478","article-title":"Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A)","volume":"116","author":"Kharasch","year":"2012","journal-title":"Anesthesiology"},{"issue":"4","key":"10.1016\/j.jsat.2021.108521_bb0255","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/clpt.2008.104","article-title":"Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance","volume":"84","author":"Kharasch","year":"2008","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"3","key":"10.1016\/j.jsat.2021.108521_bb0260","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/ALN.0b013e3181986a9a","article-title":"Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: Insights from methadone interactions with ritonavir\/indinavir","volume":"110","author":"Kharasch","year":"2009","journal-title":"Anesthesiology"},{"issue":"5","key":"10.1016\/j.jsat.2021.108521_bb0265","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1097\/ALN.0000000000000867","article-title":"Methadone pharmacogenetics: CYP2B6 polymorphisms determine plasma concentrations, clearance, and metabolism","volume":"123","author":"Kharasch","year":"2015","journal-title":"Anesthesiology"},{"issue":"3","key":"10.1016\/j.jsat.2021.108521_bb0270","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jcph.1","article-title":"Role of cytochrome P4502B6 in methadone metabolism and clearance","volume":"53","author":"Kharasch","year":"2013","journal-title":"Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1016\/j.jsat.2021.108521_bb0275","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.drugalcdep.2008.12.009","article-title":"Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity","volume":"101","author":"Kharasch","year":"2009","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1016\/j.jsat.2021.108521_bb0280","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/uog.2832","article-title":"Fetal cardiac output, distribution to the placenta and impact of placental compromise","volume":"28","author":"Kiserud","year":"2006","journal-title":"Ultrasound in Obstetrics and Gynecology"},{"issue":"3","key":"10.1016\/j.jsat.2021.108521_bb0285","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/ADM.0000000000000308","article-title":"Treating women who are pregnant and parenting for opioid use disorder and the concurrent care of their infants and children: Literature review to support national guidance","volume":"11","author":"Klaman","year":"2017","journal-title":"Journal of Addiction Medicine"},{"issue":"Suppl","key":"10.1016\/j.jsat.2021.108521_bb0290","first-page":"7","article-title":"Methadone disposition during the perinatal period in humans","volume":"11","author":"Kreek","year":"1979","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"issue":"2","key":"10.1016\/j.jsat.2021.108521_bb0295","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/10550881003684798","article-title":"Pharmacotherapy in the treatment of addiction: Methadone","volume":"29","author":"Kreek","year":"2010","journal-title":"Journal of Addictive Diseases"},{"issue":"3","key":"10.1016\/j.jsat.2021.108521_bb0300","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00007691-199606000-00001","article-title":"Stereoselective pharmacokinetics of methadone in chronic pain patients","volume":"18","author":"Kristensen","year":"1996","journal-title":"Therapeutic Drug Monitoring"},{"issue":"5","key":"10.1016\/j.jsat.2021.108521_bb0305","doi-asserted-by":"crossref","first-page":"F390","DOI":"10.1136\/adc.2003.036863","article-title":"Can methadone concentrations predict the severity of withdrawal in infants at risk of neonatal abstinence syndrome?","volume":"89","author":"Kuschel","year":"2004","journal-title":"Archives of Disease in Childhood - Fetal and Neonatal Edition"},{"issue":"1","key":"10.1016\/j.jsat.2021.108521_bb0310","doi-asserted-by":"crossref","first-page":"100075","DOI":"10.1016\/j.ajogmf.2019.100075","article-title":"Delivery dose of methadone, but not buprenorphine, is associated with the risk and severity of neonatal opiate withdrawal syndrome","volume":"2","author":"Lappen","year":"2020","journal-title":"American Journal of Obstetrics & Gynecology MFM"},{"issue":"1","key":"10.1016\/j.jsat.2021.108521_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2008.08.041","article-title":"High-dose methadone in pregnant women and its effect on duration of neonatal abstinence syndrome","volume":"200","author":"Lim","year":"2009","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"7","key":"10.1016\/j.jsat.2021.108521_bb0320","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0269881112444324","article-title":"BAP updated guidelines: Evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: Recommendations from BAP","volume":"26","author":"Lingford-Hughes","year":"2012","journal-title":"Journal of Psychopharmacology"},{"issue":"6","key":"10.1016\/j.jsat.2021.108521_bb0325","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2174\/138920012800840374","article-title":"Physiologically-based pharmacokinetic (PBPK) models for assessing the kinetics of xenobiotics during pregnancy: Achievements and shortcomings","volume":"13","author":"Lu","year":"2012","journal-title":"Current Drug Metabolism"},{"issue":"3","key":"10.1016\/j.jsat.2021.108521_bb0330","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ajog.2005.03.072","article-title":"High-dose methadone maintenance in pregnancy: Maternal and neonatal outcomes","volume":"193","author":"McCarthy","year":"2005","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1016\/j.jsat.2021.108521_bb0335","article-title":"Stereoselective analysis of methadone and EDDP in laboring women and neonates in plasma and dried blood spots and association with neonatal abstinence syndrome","author":"Metzger","year":"2020","journal-title":"American Journal of Perinatology"},{"key":"10.1016\/j.jsat.2021.108521_bb0340","article-title":"Maintenance agonist treatments for opiate-dependent pregnant women","volume":"12","author":"Minozzi","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jsat.2021.108521_bb0345","author":"National Institute for Clinical Excellence"},{"key":"10.1016\/j.jsat.2021.108521_bb0350","series-title":"Methadone","author":"National Library of Medicine","year":"2006"},{"issue":"1","key":"10.1016\/j.jsat.2021.108521_bb0355","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bcp.2004.09.008","article-title":"Bidirectional transfer of methadone across human placenta","volume":"69","author":"Nekhayeva","year":"2005","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.jsat.2021.108521_bb0360","author":"Organisation"},{"key":"10.1016\/j.jsat.2021.108521_bb0365","series-title":"United Kingdom drug situation 2019: Focal point annual report","author":"Oteo","year":"2020"},{"issue":"3","key":"10.1016\/j.jsat.2021.108521_bb0370","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jsat.2014.04.004","article-title":"Postpartum changes in methadone maintenance dose","volume":"47","author":"Pace","year":"2014","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"9","key":"10.1016\/j.jsat.2021.108521_bb0375","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2165\/11592640-000000000-00000","article-title":"Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants","volume":"50","author":"Parrott","year":"2011","journal-title":"Clinical Pharmacokinetics"},{"issue":"5","key":"10.1016\/j.jsat.2021.108521_bb0380","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2174\/138920009788897993","article-title":"Variation of drug kinetics in pregnancy","volume":"10","author":"Pavek","year":"2009","journal-title":"Current Drug Metabolism"},{"issue":"6 Pt 1","key":"10.1016\/j.jsat.2021.108521_bb0385","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1542\/peds.111.6.1429","article-title":"Methadone and breastfeeding: New horizons","volume":"111","author":"Philipp","year":"2003","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.jsat.2021.108521_bb0390","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0304-3959(88)90290-4","article-title":"Estimation of methadone clearance: Application in the management of cancer pain","volume":"33","author":"Plummer","year":"1988","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.jsat.2021.108521_bb0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(25)21130-2","article-title":"Altered methadone pharmacokinetics in methadone-maintained pregnant women","volume":"233","author":"Pond","year":"1985","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.jsat.2021.108521_bb0400","series-title":"Drug misuse and dependence: UK guidelines on clinical management","author":"Public Health England","year":"2017"},{"key":"10.1016\/j.jsat.2021.108521_bb0405","series-title":"NDTMS (national drug treatment monitoring system)","author":"Public Health England","year":"2021"},{"key":"10.1016\/j.jsat.2021.108521_bb0410","doi-asserted-by":"crossref","DOI":"10.17305\/bjbms.2020.4897","article-title":"Pharmacogenomics biomarkers for personalized methadone maintenance treatment: The mechanism and its potential use","author":"Ramli","year":"2020","journal-title":"Bosnian Journal of Basic Medical Sciences"},{"issue":"6","key":"10.1016\/j.jsat.2021.108521_bb0415","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/jps.20322","article-title":"Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases","volume":"94","author":"Rodgers","year":"2005","journal-title":"Journal of Pharmaceutical Sciences"},{"issue":"6","key":"10.1016\/j.jsat.2021.108521_bb0420","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","article-title":"Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions","volume":"95","author":"Rodgers","year":"2006","journal-title":"Journal of Pharmaceutical Sciences"},{"issue":"6","key":"10.1016\/j.jsat.2021.108521_bb0425","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0022-3476(76)81074-8","article-title":"Pharmacologic observations on the neonatal withdrawal syndrome","volume":"88","author":"Rosen","year":"1976","journal-title":"The Journal of Pediatrics"},{"issue":"1","key":"10.1016\/j.jsat.2021.108521_bb0430","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1365-2125.1999.00974.x","article-title":"Population pharmacokinetics of methadone in opiate users: Characterization of time-dependent changes","volume":"48","author":"Rostami-Hodjegan","year":"1999","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"6","key":"10.1016\/j.jsat.2021.108521_bb0435","first-page":"710","article-title":"Heart disease and pregnancy","volume":"85","author":"Siu","year":"2001"},{"key":"10.1016\/j.jsat.2021.108521_bb0440","article-title":"Is maternal methadone dose associated with the severity of neonatal abstinence syndrome?","author":"Smith","year":"2020","journal-title":"American Journal of Perinatology"},{"issue":"7","key":"10.1016\/j.jsat.2021.108521_bb0445","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1515\/jpm-2020-0106","article-title":"Comparison of buprenorphine and methadone in the management of maternal opioid use disorder in full term pregnancies","volume":"48","author":"Staszewski","year":"2020","journal-title":"Journal of Perinatal Medicine"},{"issue":"4","key":"10.1016\/j.jsat.2021.108521_bb0450","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0899-3289(20)30008-0","article-title":"Altered methadone pharmacokinetics in pregnancy: Implications for dosing","volume":"1","author":"Swift","year":"1989","journal-title":"Journal of Substance Abuse"},{"issue":"3","key":"10.1016\/j.jsat.2021.108521_bb0455","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/ALN.0b013e3181642938","article-title":"Role of CYP2B6 in stereoselective human methadone metabolism","volume":"108","author":"Totah","year":"2008","journal-title":"Anesthesiology"},{"issue":"2","key":"10.1016\/j.jsat.2021.108521_bb0460","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ajog.2004.08.030","article-title":"Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy","volume":"192","author":"Tracy","year":"2005","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1016\/j.jsat.2021.108521_bb0465","author":"U.S. Department of Justice"},{"key":"10.1016\/j.jsat.2021.108521_bb0470","author":"U.S. Food and Drug Administration"},{"issue":"3","key":"10.1016\/j.jsat.2021.108521_bb0475","first-page":"e202","article-title":"Methadone for opioid use treatment during pregnancy: Trends in postpartum dose adjustments","volume":"10","author":"Ward","year":"2020","journal-title":"AJP Reports"},{"issue":"5","key":"10.1016\/j.jsat.2021.108521_bb0480","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000381670","article-title":"Tapering from methadone or buprenorphine during pregnancy: Maternal and neonatal outcomes in Norway 1996-2009","volume":"21","author":"Welle-Strand","year":"2015","journal-title":"European Addiction Research"},{"issue":"10","key":"10.1016\/j.jsat.2021.108521_bb0485","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00228-005-0035-5","article-title":"Changes to methadone clearance during pregnancy","volume":"61","author":"Wolff","year":"2005","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1016\/j.jsat.2021.108521_bb0490","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF00315479","article-title":"Steady-state pharmacokinetics of methadone in opioid addicts","volume":"44","author":"Wolff","year":"1993","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"12","key":"10.1016\/j.jsat.2021.108521_bb0495","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1046\/j.1360-0443.2000.951217717.x","article-title":"Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: Potential clinical utility","volume":"95","author":"Wolff","year":"2000","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2021.108521_bb0500","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fgene.2013.00024","article-title":"Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): Advances on polymorphisms, mechanisms, and clinical relevance","volume":"4","author":"Zanger","year":"2013","journal-title":"Frontiers in Genetics"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221002476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221002476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:55:31Z","timestamp":1760039731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547221002476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":100,"alternative-id":["S0740547221002476"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108521","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision dosing of methadone during pregnancy: A pharmacokinetics virtual clinical trials study","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108521","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108521"}}